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Introduction {#sec1}
============

Hematopoiesis is contingent on a rare pool of self-renewing hematopoietic stem cells (HSCs) and progenitors that are regulated by a combination of a cell-extrinsic program, imparted by the bone marrow (BM) niche in which they reside, and a cell-autonomous program driven by transcription factors (TFs), which regulate gene expression ([@bib1]). Through loss-of-function genetic mouse models, the differentiation-stage requirement for specific TFs in myeloid and lymphoid committed progenitors has been characterized comprehensively ([@bib36]); yet, with few exceptions ([@bib13], [@bib23], [@bib37]), the transcriptional program critical to adult HSC survival remains unclear.

Perturbed TF activity in the form of TF chromosomal translocations and loss- or gain-of-function genetic and epigenetic mutations in TFs has been implicated in the pathogenesis of hematologic malignancies, including acute myeloid leukemia (AML). AML is driven by a subset of leukemia cells----namely leukemic stem cells (LSCs) ([@bib2])----which are acknowledged to underpin leukemic growth and maintenance and, notably, are refractory to standard AML chemotherapeutics ([@bib6], [@bib16], [@bib44]). Like their normal HSC counterparts, however, the requirement for TFs in LSC function is poorly defined; thus a deeper understanding of transcriptional regulation in this setting will afford insights toward specific targeting of LSCs, which will be necessary for improving the clinical armamentarium in AML.

*Gata2*, part of the zinc finger family of GATA family of TFs ([@bib34]), has been identified as a critical regulator of HSCs during ontogenesis of the hematopoietic system ([@bib52]). Constitutive lack of *Gata2* (*Gata2*^*−/−*^) leads to embryonic fatality at embryonic day 10.5 (E10.5) due to anemia ([@bib52]). Chimera experiments demonstrated that *Gata2*^*−/−*^ embryonic stem cells were unable to contribute to the formation of myeloid and lymphoid cells at the fetal liver (FL) developmental stage and in adult mice, suggesting that *Gata2* acts as a crucial regulator of HSCs ([@bib52]). To formally assess the requirement for *Gata2* in HSCs during embryonic development, using conditional knockout (KO) genetic models, *Gata2* has been deleted in hemogenic endothelium cells, before the generation of HSCs using *Vec-Cre* ([@bib38], [@bib30]), and immediately following HSC formation using *Vav-Cre* ([@bib38]). Through functional analysis of *Gata2*-deficient cells from temporally restricted hematopoietic organs (aorta-gonad-mesonephros, FL) in these embryonic settings, *Gata2* has been revealed as a pivotal regulator of cell-autonomous HSC generation and, thereafter, for HSC survival in the embryo. By analysis of haploinsufficient *Gata2*^*+/−*^ mice that express reduced *Gata2*, we and other laboratories have examined the impact of *Gata2* gene dosage in adult hematopoiesis ([@bib11], [@bib31], [@bib42]). BM from *Gata2*^*+/−*^ mice displayed a reduction in abundance of immunophenotypically defined HSCs and in functionality during transplantation assays ([@bib11], [@bib42]). This was associated with decreased HSC proliferation, enhanced HSC quiescence and apoptosis, and attendant downregulation of anti-apoptotic BCL-XL in *Gata2*^*+/−*^ mice ([@bib31], [@bib42]). *Gata2* haploinsufficiency also reduces granulocyte-macrophage progenitor (GMP) cell function while leaving other myeloid committed progenitors intact ([@bib43]). Conversely, forced expression of GATA2 in adult HSCs has similarly implicated *Gata2* as a critical level-dependent regulator of adult HSC proliferation and differentiation ([@bib39]).

Emphasizing the biological and clinical imperative to maintain normal GATA2 expression in adult hematopoiesis, deregulated GATA2 expression has been linked to the pathogenesis of pre-leukemic myelodysplastic syndrome (MDS) and AML. In its capacity as a tumor suppressor gene, loss of GATA2 expression in the context of sporadic or hereditary *GATA2* haploinsufficiency mutations in coding or enhancer regions leads to immunodeficiency syndromes that predispose to MDS/AML when secondary mutations are attained ([@bib12], [@bib14], [@bib47]). Far more frequently, however, GATA2 overexpression has been implicated as a harbinger of poor prognosis in adult and pediatric AML, suggesting an oncogenic role for *GATA2* in AML ([@bib32], [@bib53]). Yet the requirement for *GATA2* in AML cell fate decisions, including in the AML-propagating LSC compartment, remains poorly defined.

Using a genetic mouse model harboring conditional alleles of *Gata2* and an inducible *Mx-1-Cre* (*Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^), in which *Gata2* expression can be deleted acutely in hematopoietic cells on administration of the interferon-α mimic, polyinosinic-polycytidylic acid (pIpC), we investigated the hitherto unknown requirement for *Gata2* in adult HSCs and LSCs. We identify *Gata2* as an essential TF for adult HSC survival in BM and a unique hematopoietic TF required throughout HSC ontogeny. Using a gene knockdown (KD) approach, we independently demonstrate a conserved regulatory role for *GATA2* in human cord blood (CB) hematopoietic stem/progenitor cells (HSPCs). Finally, we show that *Gata2* regulates LSC capacity to propagate AML through modulation of self-renewal, apoptosis and myeloid differentiation fates.

Results {#sec2}
=======

Gata2 Is Essential for Cell-Autonomous Adult HSC Maintenance {#sec2.1}
------------------------------------------------------------

We first assessed *Gata2* expression in prospectively isolated HSPCs from adult BM. *Gata2* expression was highest in HSCs, multipotent progenitors and hematopoietic progenitor cells-1/-2, reduced in committed myeloid progenitor cells, and nearly extinguished in terminally differentiated blood cell populations ([Figure 1](#fig1){ref-type="fig"}A).Figure 1*Gata2* Is Essential for Cell-Autonomous HSC Maintenance(A) *Gata2* expression in hematopoietic cells compared with *Gata2* expression in HSCs (n = 3 independent experiments). Statistical analyses: one-way ANOVA.(B) Top: control and *Gata2*^*fl/fl*^*;Mx1-Cre*^+^ mice received six injections of pIpC on alternate days and were analyzed 15 or 24 days after the first injection. Bottom: GATA2 protein level in BM cells from control and *Gata2 KO* at day 24 after pIpC administration against GAPDH.(C and D) Fluorescence-activated cell sorting (FACS) plots of (C) myeloid (Gr1^+^Mac1^+^) and (D) hematopoietic stem and progenitor cells (HSPCs) from control and *Gata2 KO* mice at day 24 (n = 4).(E and F) FACS plots showing (E) myeloid cells and (F) HSPCs from control and *Gata2 KO* mice at day 15 (n = 3).(G) CD45.2^+^ BM cells from untreated control or *Gata2*^*fl/fl*^*;Mx1-Cre*^+^ mice were transplanted with CD45.1^+^ wild-type (WT) BM cells into irradiated recipients. Six weeks later, mice received six doses of pIpC. Fourteen days after last pIpC dose (day 24) mice were analyzed and CD45.2^+^ BM cells transplanted into secondary irradiated recipients.(H) Frequency of CD45.2^+^ cells in PB at week 6, before pIpC injection (n = 4).(I) Representative gel showing genotyping of donor-derived CD45.2^+^ fraction BM from pIpC-treated recipient mice. Δ, excised allele; fl, undeleted conditional allele.(J) Frequency of CD45.2^+^ cells in BM and PB at day 24 (n = 4).(K) FACS plots of CD45.1^+^ versus CD45.2^+^ chimerism in LSKs from transplanted mice at day 24 (n = 4).(L) Frequency of CD45.2^+^ cells in LSK and LK cells at day 24 (n = 4).(M) Frequency of CD45.2^+^ cells in BM and PB 4 weeks after secondary transplant (n = 4).(N) CD45.2^+^ BM cells from untreated control and *Gata2*^*fl/fl*^*;Mx1-Cre*^+^ mice were transplanted with CD45.1^+^ WT BM cells into irradiated recipients. Six weeks later, mice received six doses of pIpC and were analyzed for reconstitution for up to 16 weeks after last pIpC dose.(O) Frequency of CD45.2^+^ cells in PB after pIpC injection (n = 4). Error bars depict SD. Statistical analyses: one-way ANOVA.(P) FACS plots of CD45.1^+^ versus CD45.2^+^ chimerism in LSK cells at week 16 (n = 3).(Q) Representative gel showing genotyping of donor CD45.2^+^ fraction of the BM and PB of pIpC-treated recipients at week 16. Δ, excised allele; fl, undeleted conditional allele.Data are mean ± SEM and n denotes number of mice used per genotype unless otherwise stated. Statistical analyses: Mann-Whitney U test unless otherwise indicated. ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Next, to assess the requirement for *Gata2* in adult HSC maintenance, we bred *Gata2* harboring conditional alleles of *Gata2* (*Gata2*^*fl/fl*^ mice) with *Mx1-Cre* to obtain a cohort of *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ or control mice (*Gata2*^*fl/fl*^*;Mx1-Cre*^*−*^) and administered pIpC on alternate days for 10 days to achieve acute deletion of *Gata2* (*Gata2 KO*). The impact of *Gata2* on hematopoiesis was assessed 14 days after the last injection of pIpC ([Figure 1](#fig1){ref-type="fig"}B). Near complete loss of GATA2 protein and *Gata2* transcript was confirmed in BM by western blot and qPCR analysis, respectively ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}A). BM cellularity was significantly attenuated in *Gata2 KO* mice in comparison with control mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Immunophenotypic analysis revealed that, while lymphoid lineages remained intact, a striking reduction of myeloid and erythroid cells was observed in the BM and/or peripheral blood (PB) of *Gata2 KO* mice ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). To identify the origin of myeloid and erythroid cell loss in the context of *Gata2* deficiency, we assessed HSPCs from BM of *Gata2 KO* mice and found a near complete loss of cells in the LSK compartment (which contain HSCs and primitive progenitor cells) and LK compartment (comprising committed myeloid and erythroid progenitors) ([Figure 1](#fig1){ref-type="fig"}D). To investigate the kinetics of HSC loss after *Gata2* deletion, we assessed the BM of *Gata2 KO* mice 5 days after the last pIpC dose ([Figure 1](#fig1){ref-type="fig"}B). Remarkably, we observed a near complete depletion of myeloid cells and LSK and LK cells by day 5 ([Figures 1](#fig1){ref-type="fig"}E and 1F), indicating a rapid loss of HSCs immediately following *Gata2* deletion, consistent with a profound HSC survival defect.

*Mx1-Cre* mediates gene deletion in hematopoietic cells, extramedullary tissues, and in the BM niche ([@bib24]). To stringently evaluate whether *Gata2* functions to regulate HSC maintenance cell autonomously, we transplanted CD45.2^+^ BM cells from *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ or control mice, which have not received pIpC, together with unfractionated CD45.1^+^ BM cells in a competitive transplant ([Figure 1](#fig1){ref-type="fig"}G). Similar engraftment was observed in the PB of recipients transplanted with *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ and control cells before *Gata2* deletion ([Figure 1](#fig1){ref-type="fig"}H). Six weeks after transplantation, *Gata2* deletion was induced by pIpC administration, and efficient *Gata2* deletion in CD45.2^+^ BM cells of recipients transplanted with *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ cells was confirmed 14 days after the last pIpC dose ([Figure 1](#fig1){ref-type="fig"}I). We observed a decrease in the frequency of CD45.2^+^ *Gata2 KO* cells in BM, and to a lesser extent in PB ([Figure 1](#fig1){ref-type="fig"}J). Further immunophenotypic analysis revealed a complete loss of myeloid cells in BM and PB and a significant reduction of erythroid cells in BM ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). Strikingly, only CD45.1^+^ BM support cells were able to contribute to HSPC maintenance; no CD45.2^+^ *Gata2 KO* cells were detectable within the LSK and LK compartments ([Figures 1](#fig1){ref-type="fig"}K and 1L). To test that HSPC loss was not merely due to an attenuation of cell surface markers that define HSCs, such as Sca-1 and c-kit, we isolated vestigial *Gata2 KO* CD45.2^+^ BM cells from primary recipients and transplanted them together with unfractionated CD45.1^+^ competitor cells into secondary recipients ([Figure 1](#fig1){ref-type="fig"}G). Four weeks after transplantation we found no *Gata2 KO* cells in the BM or PB of the mice transplanted with *Gata2 KO* BM cells ([Figure 1](#fig1){ref-type="fig"}M).

Having shown entire loss of the myeloid lineage while lymphoid cells were preserved at 14 days after the last injection of pIpC in the BM of *Gata2 KO* mice, we next investigated whether the lack of multi-lineage failure after *Gata2* deletion was due to the relatively longer lifespan of lymphoid cells compared with myeloid cells. To test this directly, we performed a long-term transplantation assay to abolish *Gata2* expression in a cell-autonomous manner and monitored mice for 16 weeks to study the impact of *Gata2* deletion on long-term hematopoiesis ([Figure 1](#fig1){ref-type="fig"}N). Analysis of PB revealed a continual decline in contribution of *Gata2 KO* cells to blood lineages of recipient mice, with less than 5% engraftment of *Gata2 KO* cells detectable at 16 weeks after *Gata2* deletion, indicating a multi-lineage defect in *Gata2 KO* cells ([Figure 1](#fig1){ref-type="fig"}O). In addition, BM analysis showed an absence of CD45.2^+^ *Gata2 KO* BM cells in the LSK compartment at 16 weeks ([Figure 1](#fig1){ref-type="fig"}P). Full deletion of the *Gata2* gene was achieved in residual PB and BM *Gata2 KO* cells at 16 weeks ([Figure 1](#fig1){ref-type="fig"}Q).

To eliminate the possibility of *Gata2-*dependent extrinsic HSC regulation through the BM niche, we transplanted unfractionated CD45.1^+^ BM cells into lethally irradiated CD45.2^+^ *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ or control mice. Six weeks after transplantation, we administered pIpC to obtain *Gata2*-deficient (*Gata2 KO*) or control BM niche recipient mice and monitored the engraftment for up to 12 weeks ([Figure S1](#mmc1){ref-type="supplementary-material"}G). The frequency of CD45.1^+^ cells in the PB of *Gata2 KO* recipients remained comparable with those transplanted in control mice ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1I). In concert, these data demonstrate that *Gata2* is critically required for cell-autonomous maintenance of HSCs and multi-lineage hematopoiesis.

GATA2 Regulates Human CB HSPC Function {#sec2.2}
--------------------------------------

Having shown the requirement for *Gata2* in mouse adult HSC function, we next sought to assess whether this role was conserved in human HSPCs. Using a bicistronic lentiviral vector system carrying a GFP reporter and short hairpin (shRNA) targeted to *GATA2* expression in CB CD34^+^ HSPCs, we conducted functional analysis in colony-forming cells (CFCs) and long-term culture-initiating cell (LTC-IC) assays following *GATA2* KD ([Figure 2](#fig2){ref-type="fig"}A). Reduction in *GATA2* expression was confirmed in CB CD34^+^ cells transduced with two independent KD constructs ([Figure 2](#fig2){ref-type="fig"}B). Overall CFC growth capacity and lineage-specific CFCs (e.g., BFU-E) were markedly reduced using either *GATA2* KD constructs ([Figure 2](#fig2){ref-type="fig"}C). Limiting dilution LTC-IC analysis revealed a marked reduction in HSPC frequency using both KD constructs, in keeping with the lack of multipotent progenitors (CFC-GEMM) observed in CFC assays following *GATA2* KD ([Figures 2](#fig2){ref-type="fig"}C and 2D). Together these data demonstrate that *GATA2* functions as a critical regulator of human HSPC function.Figure 2*GATA2* Is a Crucial Regulator of Human CB HSPC Function(A) CB CD34^+^ cells were transduced with lentiviruses encoding a short hairpin against human GATA2 (or scramble control) and a GFP reporter. GFP^+^ cells were FACS sorted and plated into CFC or LTC-IC.(B) Relative *GATA2* mRNA expression in CB CD34^+^ cells compared with *GAPDH* (n = 3 independent experiments).(C) Colony-forming units (CFU) per 500 CD34^+^ GFP^+^ cells plated (n = 3 independent experiments). Statistical analyses: one-way ANOVA. Data are mean ± SEM.(D) Top: plot showing representative log-fraction of the limiting dilution model for the LTC-IC assay. The dotted lines give the 95% confidence interval. Bottom: LTC-IC frequency calculated using ELDA software (n = 2 independent experiments).^∗^p \< 0.05, ^∗∗∗∗^p \< 0.0001.

Acute Deletion of Gata2 Impairs LSC Maintenance and Self-Renewal in Meis1a/Hoxa9-Driven AML {#sec2.3}
-------------------------------------------------------------------------------------------

To investigate the requirement of *Gata2* in LSCs, we employed a tractable retroviral leukemogenic assay in which leukemic transformation of murine C-KIT^+^ HSPCs is driven by overexpression of *Meis1a/Hoxa9*, which is observed in 40% of AML patients ([@bib8], [@bib28]). *Meis1a/Hoxa9*-transduced cells were serially replated for three rounds in a CFC assay to generate pre-LSCs, which, when injected into primary lethally irradiated mice, become LSCs and cause AML ([Figure 3](#fig3){ref-type="fig"}A). Given that *Gata2*^*fl/fl*^;*Mx1-Cre*^*+*^ mice lack HSPCs by day 15 after pIpC administration ([Figure 1](#fig1){ref-type="fig"}F), we instead co-transduced HSPCs from non-induced *Gata2*^*fl/fl*^;*Mx1-Cre*^*+*^ or control mice with retroviruses expressing *Meis1a* and *Hoxa9*, and after three rounds of CFC we harvested *Meis1a/Hoxa9* pre-LSC and transplanted them into primary recipients together with unfractionated BM support cells ([Figure 3](#fig3){ref-type="fig"}A). We monitored leukemia development by episodic bleedings ([Figure 3](#fig3){ref-type="fig"}B) and induced *Gata2* deletion with pIpC once the percentage of leukemic cells in the PB reached 20%--25%, a threshold for the diagnosis of AML. Leukemia cells in the PB of recipients transplanted with *Gata2*^*fl/fl*^;*Mx1-Cre*^*+*^ pre-LSCs were dramatically reduced at weeks 4 and 6 after pIpC treatment ([Figure 3](#fig3){ref-type="fig"}C). Consistent with this, recipients of *Gata2 KO* LSCs succumbed to AML with a significantly delayed latency compared with recipients of control LSCs, indicating that *Gata2* deletion impairs LSC maintenance ([Figure 3](#fig3){ref-type="fig"}D). Notably, these results were obtained with 33% recipients harboring *Gata2 KO* leukemic cells with complete *Gata2* deletion.Figure 3Acute Deletion of *Gata2* Impairs LSC Development and Self-Renewal(A) C-kit^+^ cells from control or *Gata2*^*fl/fl*^*;Mx1-Cre*^*+*^ mice were transduced with retroviruses expressing *Meis1a/Hoxa9* and plated into CFC assays. After CFC3, pre-LSCs (CD45.2^+^ c-kit^+^) were sorted and transplanted into lethally irradiated recipients with CD45.1^+^ unfractionated BM cells. Three weeks later, mice were injected with pIpC. LSCs (CD45.2^+^ c-kit^+^) from primary recipients were transplanted into secondary recipients.(B) Frequency of leukemic (CD45.2^+^) cells in PB before pIpC (n = 6).(C) Frequency of leukemic cells in PB at the indicated days after pIpC injection (n = 6). Statistical analyses: one-way ANOVA.(D) Kaplan-Meier survival curve of recipients transplanted with pre-LSCs (n = 6). Statistical analyses: Mantel-Cox test.(E) Kaplan-Meier survival curve of recipients transplanted with LSCs (n = 6--8). Statistical analyses: Mantel-Cox test.(F) Pre-LSCs (CD45.2^+^ c-kit^+^) from the two genotypes were sorted and transplanted into lethally irradiated recipients together with CD45.1^+^ unfractionated BM cells. Three weeks later, mice were injected with pIpC, and were analyzed or used for RNA-seq 7 days after the last dose of pIpC.(G) Frequency of leukemic cells in PB before and after pIpC (n = 6--7).(H) Representative images of reduced splenomegaly in *Gata2 KO* mice.(I) Spleen weight at day 7 (n = 6--7).(J and K) Frequency of leukemic cells in (J) SP and in (K) BM at day 7 (n = 6--7).(L) Representative FACS plot of LSCs in BM.(M) Frequency of LSCs (CD45.2^+^ c-kit^+^) in BM at day 7 (n = 6--7).(N) Representative gel showing genotyping from donor-derived LSC fraction of the BM of pIpC-treated recipient mice at day 7. Δ, excised allele; fl, undeleted conditional allele.Data are mean ± SEM and n denotes number of mice used per genotype. Statistical analyses: Mann-Whitney U test unless otherwise stated. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

To investigate whether *Gata2* deletion also compromises LSC self-renewal, we prospectively isolated LSCs from BM of mice exhibiting complete deletion of *Gata2* or controls by fluorescence-activated cell sorting and transplanted them into secondary recipients together with unfractionated BM support cells ([Figure 3](#fig3){ref-type="fig"}A). Recipients transplanted with *Gata2 KO* LSCs developed AML more slowly than recipients transplanted with control LSCs ([Figure 3](#fig3){ref-type="fig"}E). Taken together, these data demonstrate that *Gata2* is required for LSC maintenance, self-renewal, and leukemia propagation in a *Meis1a/Hoxa9*-driven AML mouse model.

That recipients of *Gata2 KO* LSCs eventually succumb to AML demonstrates that, in striking contrast to their normal HSC counterparts ([Figure 1](#fig1){ref-type="fig"}), LSCs survive *Gata2* loss, suggesting differential requirements for *Gata2* in subsets of C-KIT^+^ HSPCs during transformation. The cell of origin for *Meis1a/Hoxa9*-driven AML in C-KIT^+^ HSPCs is either LSK or common myeloid progenitor (CMP) but not GMP ([@bib58]). We investigated which of these HSPC subsets was dependent on *Gata2* during transformation in *Meis1a/Hoxa9*-driven AML. *Meis1a/Hoxa9* LSK and CMP-derived pre-LSCs from *Gata2*^*fl/fl*^ or *Gata2*^*+/+*^ mice were transduced with lentiviruses encoding Cre and *iVenus* reporter. Transduced *iVenus*^*+*^ cells were serially plated in CFC assays for three rounds, and were immunophenotypically assessed at each stage for expression of C-KIT^+^, as a marker of LSCs, and GR1 and MAC1 myeloid differentiation markers, which are blocked in AML development. While LSC and MAC1 expression was similar between genotypes in LSK and CMP compartments throughout replating ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D), LSK cells from *Gata2 KO* had enhanced GR1 expression in CFC3 ([Figure S2](#mmc1){ref-type="supplementary-material"}E). In contrast, a relative blockade in GR1 expression was observed from *Gata2 KO* in *Meis1a/Hoxa9*-transformed CMP at CFC3 ([Figure S2](#mmc1){ref-type="supplementary-material"}F). These data suggest that HSC-enriched LSKs mediate GATA2 regulation of transformation in *Meis1/Hoxa9* AML, whereas CMPs regulate transformation in this setting independently of GATA2.

Acute Deletion of Gata2 Promotes an LSC-Specific Program of Apoptosis and Myeloid Differentiation in Meis1a/Hoxa9-Driven AML {#sec2.4}
----------------------------------------------------------------------------------------------------------------------------

To examine the molecular signature governing LSC maintenance and self-renewal driven by GATA2, we performed global gene expression analysis by RNA sequencing (RNA-seq) of *Gata2 KO* and control LSCs. MEIS1a and HOXA9 expressing pre-LSCs (CD45.2^+^ c-kit^+^) were transplanted into lethally irradiated recipient mice together with unfractionated CD45.1^+^ BM support cells ([Figure 3](#fig3){ref-type="fig"}F). When the levels of AML in PB reached 25%, we administered pIpC to delete *Gata2* in LSCs and analyzed mice 7 days after the last dose of pIpC ([Figure 3](#fig3){ref-type="fig"}F). The frequency of AML cells in PB was comparable between both genotypes before pIpC administration ([Figure 3](#fig3){ref-type="fig"}G), yet in mice harboring *Gata2 KO* LSCs there was a 3.5-fold reduction in the PB at 7 days after administration of the last dose of pIpC ([Figure 3](#fig3){ref-type="fig"}G). Splenomegaly, a hallmark of AML, was markedly reduced in recipients with *Gata2 KO* LSCs 7 days after the last pIpC injection ([Figures 3](#fig3){ref-type="fig"}H and 3I). This corresponded to a reduced population of engrafting AML cells in the spleen of *Gata2 KO* LSC recipients ([Figure 3](#fig3){ref-type="fig"}J). Immunophenotypic analysis was also conducted on BM, which revealed a decrease in bulk AML cells and a 3-fold reduction in the abundance of LSC (CD45.2^+^ c-kit^+^) in recipients harboring *Gata2 KO* LSCs ([Figures 3](#fig3){ref-type="fig"}K--3M). Full deletion of *Gata2* was achieved in *Gata2 KO* LSCs ([Figure 3](#fig3){ref-type="fig"}N). Using pathway analysis of RNA-seq using the Gene Ontology Consortium and gene set enrichment analysis, we observed differential upregulation of pathways modulating metabolic processes and pathways that curtail cell proliferation and downregulation of G-coupled receptor signaling, oxidative phosphorylation, and C-MYC target genes in *Gata2 KO* LSCs ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Furthermore, *Gata2 KO* LSCs exhibited dampening of lysosome signaling, which targets AML LSCs ([@bib48]), and the nuclear factor κB signaling pathway, the activation of which is associated with a pro-inflammatory environment permissive for the development and maintenance of AML ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) ([@bib57], [@bib61]).Figure 4Transcriptional Signature of *Gata2 KO* LSCs Shows Deregulated Apoptotic and Myeloid Differentiation PathwaysGene expression analyses were performed in sorted control or *Gata2 KO* LSCs using the same experimental design as [Figure 3](#fig3){ref-type="fig"}F (n = 4 mice per genotype).(A) Biological processes enriched in up- and downregulated genes in *Gata2 KO* LSCs compared with control LSCs. Analyses was performed using the Gene Ontology Consortium database. Data are shown as --log10 (p value), and the dotted orange line indicates p value = 0.05.(B and C) Heat maps reflecting expression levels of (B) apoptotic genes and regulators of AML leukemogenesis, and (C) Gata2 target genes, and myeloid and lymphoid differentiation-associated genes that are significantly differentially expressed between control or Gata2 KO LSCs. (D) GSEA plots showing apoptosis and stem cell differentiation signature gene sets.

To identify GATA2 target genes specific to LSCs rather than HSCs, we compared RNA-seq data from *Gata2 KO* LSCs with GATA2 target genes identified from HSCs. As genetic deletion of *Gata2* entirely abolishes immunophenotypically defined HSCs ([Figure 1](#fig1){ref-type="fig"}), we instead conducted RNA-seq on HSCs from *Gata2* haploinsufficient mice bearing a single floxed allele deleted by *Vav-iCre* (*Gata2*^*+/fl*^*;Vav-iCre*^*+*^) *in vivo*, where adult HSCs remain isolatable but are reduced in abundance ([@bib38]) (our unpublished observations). Using Ingenuity Pathway Analysis of differentially expressed genes in HSCs and LSCs, we found that several GATA2-mediated biological pathways, including ERK/MAPK and interleukin-4 signaling, were shared between HSCs and LSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Seventy genes were differentially expressed in *Gata2*^*+/fl*^*;Vav-iCre*^*+*^ HSCs and 689 differentially expressed in *Gata2 KO* LSCs, yet a mere 4 GATA2 target genes (Lphn2, Mllt3, Gimap4, and Zhx2) were common to both HSCs and LSCs. Thus, the vast majority of GATA2 target genes identified here were exclusive to LSCs. In agreement with the notion that lack of *Gata2* engenders an anti-leukemic effect in LSCs, established AML tumor suppressors or oncogenes were up- or downregulated, respectively, in *Gata2 KO* LSCs ([Figure 4](#fig4){ref-type="fig"}B). As expected, previously identified GATA2 target genes were deregulated in *Gata2 KO* LSCs ([Figure 4](#fig4){ref-type="fig"}C). We observed gene signatures in *Gata2 KO* LSCs consistent with re-activation of both lymphoid and erythroid differentiation potential (e.g., Epo-R) ([Figure 4](#fig4){ref-type="fig"}C). Most notably, *Gata2 KO* LSCs registered a robust pro-apoptotic and myeloid cell differentiation gene signature ([Figures 4](#fig4){ref-type="fig"}A--4D). These data suggest that ablation of *Gata2* could alleviate the myeloid differentiation and apoptotic block in AML LSCs----cell fates that are characteristic and indispensable for facilitating AML maintenance and propagation ([@bib16], [@bib50]).

Next, to directly assess whether apoptosis was augmented in *Gata2 KO* LSCs, we conducted an annexin V assay on *Gata2 KO* LSCs at 7 days after the last pIpC injection ([Figure 3](#fig3){ref-type="fig"}F), which indeed confirmed an increase in apoptosis ([Figure 5](#fig5){ref-type="fig"}A). Using intracellular flow cytometry, we measured protein levels of crucial apoptotic regulators in *Gata2 KO* LSCs or control LSCs. Between *Gata2 KO* LSCs and their LSC control counterparts, no changes were discernible with respect to the mean fluorescence intensity (MFI) of P53, or the activation of the survival-promoting phosphatidylinositol 3-kinase-AKT ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Given that BCL-XL regulates cell survival in the context of GATA factor-dependent erythroid cell differentiation ([@bib10]), we assessed BCL-XL expression in *Gata2* KO LSCs and *Gata2* haploinsufficient HSCs from both *Mx1-Cre* or *Vav-iCre* systems, but found that expression was unperturbed in all settings ([Figures S3](#mmc1){ref-type="supplementary-material"}F, S3H, and S3J). In stark contrast, a significant reduction in the MFI of anti-apoptotic protein BCL2 was found only in *Gata2 KO* LSCs ([Figures 5](#fig5){ref-type="fig"}B, 5C, [S3](#mmc1){ref-type="supplementary-material"}G, and S3I). Thus, acute deletion of *Gata2* produces a rapid loss of LSCs, consistent with perturbed cell survival and mediated partly by attenuation of BCL2 expression. Furthermore, GATA2-mediated regulation of *Bcl2* in LSCs represents a novel GATA-dependent cell survival mechanism specific to LSCs rather than HSCs.Figure 5Deletion of *Gata2* in LSCs Leads to an Increase in Apoptosis and Enhanced Myeloid DifferentiationAnalyses were performed in control or *Gata2 KO* LSCs using the experimental design in [Figure 3](#fig3){ref-type="fig"}F.(A) Frequency of annexin V^+^ cells in LSCs (n = 6--7).(B) Representative histogram plot showing the levels of BCL2 protein in control and *Gata2 KO* LSCs.(C) MFI of BCL2 in LSCs in relation to the MFI of isotype control (n = 6--7).(D) Representative histogram plot showing the levels of Mac1 and Gr1 protein in leukemic cells. Red dotted line indicates the highest expression of each marker.(E) Gating strategy to distinguish AML blast cells with differentially expressed Gr1 and Mac1 levels: Gr1^high^Mac1^high^, Gr1^low^Mac1^high^, Gr1^high^Mac1^low^, and Gr1^low^Mac1^low^. Representative FACS plots showing an increase in Gr1^high^Mac1^high^ population after deletion of *Gata2* in LSCs.(F) Frequency of the indicated populations in BM of leukemic mice (n = 6--7). Statistical analyses: one-way ANOVA.Data are mean ± SEM and n denotes number of mice used per genotype. Statistical analyses: Mann-Whitney U test unless otherwise indicated. ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Having identified an enhanced myeloid differentiation gene signature in *Gata2 KO* LSCs, we next asked whether this reflected GATA2-mediated alterations in myeloid differentiation of AML blasts *in vivo*. Using immunophenotyping, we analyzed the differentiation status of total BM from mice harboring *Gata2 KO* LSCs at 7 days after the last pIpC injection ([Figure 3](#fig3){ref-type="fig"}F). A trend toward increased GR1 or MAC1 expression was observed in bulk AML cells derived from *Gata2 KO* LSCs ([Figure 5](#fig5){ref-type="fig"}D), which mapped specifically to a significant increase in the abundance of GR1^high^MAC^high^ myeloid cells ([Figures 5](#fig5){ref-type="fig"}E--5F). Together with gene expression profiling data of *Gata2 KO* LSCs, these data support the contention that ablation of *Gata2* in LSCs increases their differentiation capacity *in vivo*, raising the possibility that targeting the GATA2 differentiation affiliated transcriptional network in LSCs could pave the way toward novel therapeutics in AML.

Discussion {#sec3}
==========

In this report, to explore the genetic requirement for *Gata2* in adult hematopoiesis, we employed a conditional gene-targeting approach using the *Mx1*-Cre system to specifically delete *Gata2* in hematopoietic cells from adult mice. Consistent with data using *ER*-Cre-mediated deletion of the *Gata2* C-terminal zinc-finger domain ([@bib29]), we demonstrate that acute genetic ablation of *Gata2* leads to a rapid and complete cell-autonomous loss of adult HSCs and multi-lineage potential. Therefore, *Gata2* joins a select list of TFs that are indispensable for adult HSC maintenance and survival ([@bib13], [@bib23], [@bib37]). Loss-of-function studies in mice have identified various TFs required for distinct temporal and developmental stages of hematopoiesis, as typified by *Runx1*, which is required for HSC generation from hemogenic endothelium, but expendable for HSC maintenance for the remainder of gestation and in adult HSCs in the BM ([@bib4]). *Cited2*, a reported upstream regulator of *Gata2* in hematopoiesis ([@bib45]), is a pivotal functional regulator of embryonic and adult HSCs, yet genetic KO models also highlight key stage-specific requirements during HSC development. For example, conditional genetic KO of *Cited2* in adult hematopoiesis using *Mx1-Cre* demonstrated the requirement for *Cited2* in adult HSC survival via *Ink4a/Arf* and *p53* ([@bib23]). In contrast, conventional germline deletion of *Cited2* produced isolatable HSCs at the FL stage, although *Cited2*^*−/−*^ HSCs were impaired both in abundance and functionality ([@bib5]). Here, in concert with data from [@bib38], we importantly define *Gata2* as a unique TF that is necessary throughout HSC ontogenesis----from cell-autonomous HSC generation (using the *Vec-Cre* system) and HSC survival (using the *Vav-Cre* model) in the nascent blood system of the embryo to adult HSC maintenance in BM. *Evi1*, another upstream regulator of *Gata2* in hematopoiesis, mirrors the requirement of *Gata2* for HSC survival during development and in the adult ([@bib9], [@bib46], [@bib60]), although the explicit requirement for *Evi1* in HSC generation from hemogenic endothelium in the embryo remains untested and merits further investigation.

Using a lentiviral-based shRNA KD approach, we extended this study to examine the currently ill-defined requirement for *GATA2* in human HSPCs. Mirroring data from the *Mx1-Cre* genetic mouse model, we observed that reducing GATA2 expression in human CB CD34^+^ cells profoundly altered HSPC function, as assessed by CFC and LTC-IC assays. Together, these data identify *GATA2* as a regulator of human HSPCs, which may bear relevance for understanding clinical *GATA2* haploinsufficiency syndromes ([@bib7], [@bib12], [@bib19], [@bib47]), in which the impact of *GATA2* mutations in HSPCs remains unclear. Identifying and characterizing the genetic and epigenetic dependencies of specific HSPC population(s) transformed by loss-of-function *GATA2* mutations and associated secondary mutations, such as *ASXL1*, may offer mechanistic insights into the wide range of complex pathologies and lineage-specific hematopoietic effects eventually leading to MDS/AML in *GATA2* haploinsufficiency syndromes.

Considering that accumulating evidence also suggests an oncogenic function for *GATA2* when it is overexpressed in pediatric and adult AML ([@bib32], [@bib53]), we elected to interrogate the requirement for *Gata2* in LSCs by using an *in vivo* model of AML driven by *Meis1a/Hoxa9*. Genetic deletion of *Gata2* delayed *in vivo* AML development by impairing the maintenance and self-renewal of LSCs. Of note, gene expression patterns in *Gata2 KO* LSCs diametrically opposed those observed in the setting of either *Gata2* overexpression- or in *Gata2* haploinsufficiency-related models ([@bib18], [@bib35], [@bib51]). For example, lymphoid differentiation blockade and *c-Myc* expression activation has been observed in the context of *Gata2* overexpression studies ([@bib35], [@bib51]), whereas *Gata2 KO* LSCs display a gene signature consistent with reactivation of lymphoid differentiation and downregulation of MYC target genes. Similarly, in leukemic cells from *Gata2* haploinsufficiency-related models ([@bib18]), in which *Gata2* acts as a tumor suppressor rather than an oncogene, enrichment for oxidative phosphorylation and MYC target genes was observed, yet *Gata2 KO* LSCs from *Meis1a/Hoxa9* AML demonstrate reduction in oxidative phosphorylation pathways. Thus, ablation of *Gata2* in LSCs pares down pro-oncogenic stimuli indicating the potential for therapeutic intervention in AML.

To this end, deletion of *Gata2* enhanced LSC apoptosis, enriched for a pro-apoptotic and myeloid differentiation signature in LSCs, and caused AML blast cell differentiation, suggesting that characteristic biological traits of AML----enhanced leukemic cell survival and a myeloid differentiation block----can be ameliorated through inhibition of GATA2 or targeting the GATA2 transcriptional network in LSCs. Whether direct, transient inhibition of GATA2 in LSCs is a possibility remains to be tested and is questionable given the pivotal role identified here for *Gata2* in adult hematopoiesis and the known tumor-promoting role of *GATA2* in the context of haploinsufficiency. However, in favor of this proposition, the proteasome inhibitor K7174, which inhibits GATA2, has been found to be beneficial in the treatment of multiple myeloma ([@bib15], [@bib20], [@bib33]). We speculate that, alternatively, it may be feasible to selectively target the GATA2 transcriptional network in LSCs as GATA2 LSC target genes identified here were specific to LSCs and not HSCs ([@bib17], [@bib21]), which likely reflects differential transcriptional dependencies for *Gata2* in different cellular contexts ([@bib42], [@bib43]).

Our study suggests that the GATA2 pro-apoptotic transcriptional network in LSCs, exemplified by *Bcl2*, may be particularly susceptible to therapeutic targeting in AML, while sparing normal HSPCs ([@bib26], [@bib40]). Auspiciously, responses of BCL2 pharmacological inhibitor, venetoclax, in combination with standard AML chemotherapy agents, cytarabine, or hypomethylating agents, azacytidine and decitabine, are favorable compared with conventional induction therapy ([@bib22]). Furthermore, venetoclax resistance in AML may be circumvented by using an inhibitor toward another BCL2 family member, MCL1 ([@bib41]).

The characteristic myeloid differentiation block observed in AML has been overcome successfully in a subtype of AML, acute promyelocytic leukemia (APL), where a combination of all-*trans* retinoic acid (ATRA) and arsenic trioxide (ATO) has now become the mainstay of treatment for APL patients ([@bib27]). Evidence suggests that the combination of ATRA and ATO cures APL by invoking myeloid differentiation in LSCs and their progeny, AML blasts, thereby precipitating LSC exhaustion ([@bib59], [@bib62]). However, attempts to replicate induction of myeloid differentiation in a similar manner across the genetic and clinically diverse AML subtypes have met with limited success ([@bib49]). We show here that ablation of *Gata2* in a non-APL AML model of LSCs overrides the myeloid differentiation block coupled to a depletion of LSC survival and self-renewal ability, presumably by promoting myeloid differentiation and apoptosis at the expense of self-renewing LSCs. Because LSCs are central to therapy resistance and relapse in AML ([@bib6], [@bib16], [@bib44]), further investigation into how these LSC cell fates are coordinated and transcriptionally regulated by GATA2 should lead to an understanding of whether combinatorial therapies are needed to effectively exhaust the functionality of LSCs in AML.

Finally, the data presented here should also have direct relevance to cancer stem cell (CSC) biology beyond AML. Bearing in mind that LSCs serve as a paradigm for CSCs in other tissues, this study may hold significant importance for understanding GATA2-mediated transcriptional programming and developing clinical therapies against CSCs in prostate and lung cancer, in which GATA2 is overexpressed and linked to aggressiveness ([@bib25], [@bib54]).

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Gene targeting of *Gata2*^*fl/fl*^ mice has been described previously ([@bib3]), and mice were provided by Prof. Julian Downward. *Gata2*^*fl/fl*^ mice were bred with *Mx1-Cre* and *Vav-iCre* mice ([@bib56]). *Gata2* conditional gene deletion in the *Mx1-Cre* model was achieved by administration of six to eight intraperitoneal injections of pIpC every other day (0.25 mg per dose; GE Healthcare). All animals used for experiments were 8- to 12 weeks old in a C57BL/6 genetic background in accordance with UK Home Office regulations.

Meis1a/Hoxa9 Leukemic Transformation Assay {#sec4.2}
------------------------------------------

Meis1a-puro and Hoxa9-neo MSCV plasmids were used as described previously ([@bib55]). Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Transplantation Assays {#sec4.3}
----------------------

C57BL/6 SJL (CD45.1), or C57BL/6 (CD45.2) for niche experiment, adult recipient mice were irradiated with a split dose of 1,000 cGy (^137^Cs source) 24 h before transplantation. Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Flow Cytometry {#sec4.4}
--------------

Samples were analyzed with a BD LSRFortessa and sorting experiments were performed with a FACSAria Fusion (BD Biosciences). Antibodies used are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

CB CD34^+^ HSPCs Isolation and Culture {#sec4.5}
--------------------------------------

Umbilical CB was obtained from full-term healthy pregnancies at the Maternity Unit of the University Hospital of Wales, Cardiff, following informed consent and approval from the South East Wales Research Ethics Committee in accordance with the 1964 Declaration of Helsinki. Further detailed information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

qRT-PCR and Western Blot {#sec4.6}
------------------------

Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-Seq and Bioinformatics {#sec4.7}
--------------------------

RNA-seq was performed on CD45.2^+^c-kit^+^ LSCs. Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.8}
--------------------

Further information provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S3, and Table S1Document S2. Article plus Supplemental Information

Supported by the British Society for Hematology, Life Science Research Network Wales, Leukemia Cancer Society, Leukemia Research Appeal for Wales and the Lady Tata Memorial Trust (to N.P.R). K.R.K. is a Cancer Research UK (CRUK) Senior Cancer Research Fellow and a CRUK Program Grant holder. We thank Robert Andrews for help with bioinformatic analyses.

Supplemental Information can be found online at <https://doi.org/10.1016/j.stemcr.2019.07.005>.

[^1]: Co-first author
